1. Home
  2. ORGN vs ACOG Comparison

ORGN vs ACOG Comparison

Compare ORGN & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$0.20

Market Cap

109.4M

Sector

Industrials

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.88

Market Cap

115.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGN
ACOG
Founded
2008
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
109.4M
115.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ORGN
ACOG
Price
$0.20
$5.88
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
3.0M
84.2K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,122,000.00
$7,427,199.00
Revenue This Year
$49.18
N/A
Revenue Next Year
$144.81
$132.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$3.75
52 Week High
$1.12
$11.54

Technical Indicators

Market Signals
Indicator
ORGN
ACOG
Relative Strength Index (RSI) N/A 44.35
Support Level N/A $6.11
Resistance Level N/A $6.62
Average True Range (ATR) 0.00 0.42
MACD 0.00 -0.04
Stochastic Oscillator 0.00 2.77

Price Performance

Historical Comparison
ORGN
ACOG

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: